Exploring 3 High Growth Tech Stocks In The US Market
The U.S. stock market is showing resilience, particularly in the tech sector, with the Nasdaq gaining 0.5%. Amid market volatility, high-growth tech stocks are being spotlighted, including MiMedx Group, National CineMedia, and Simulations Plus, each demonstrating strong innovation and adaptability. MiMedx Group is optimistic about revenue growth despite recent earnings volatility, while National CineMedia is navigating financial challenges but projects revenue increases. Simulations Plus focuses on AI-driven drug discovery, with significant expected earnings growth. These companies exemplify the potential for growth in the current economic landscape.
As major U.S. stock indexes recently closed higher, rebounding from a losing week amid concerns over a potential government shutdown, the tech-heavy Nasdaq showed resilience with a 0.5% gain. In this context of market volatility and economic uncertainty, identifying high-growth tech stocks involves evaluating companies that demonstrate strong innovation capabilities and adaptability to rapidly changing market conditions.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| ACADIA Pharmaceuticals | 10.33% | 23.81% | ★★★★★☆ |
| ADMA Biologics | 20.60% | 23.25% | ★★★★★☆ |
| Palantir Technologies | 25.11% | 31.65% | ★★★★★★ |
| RenovoRx | 65.52% | 68.63% | ★★★★★☆ |
| Workday | 11.20% | 32.07% | ★★★★★☆ |
| OS Therapies | 56.64% | 68.61% | ★★★★★☆ |
| Circle Internet Group | 28.59% | 82.71% | ★★★★★☆ |
| Aldeyra Therapeutics | 42.88% | 74.81% | ★★★★★☆ |
| Vanda Pharmaceuticals | 22.66% | 59.11% | ★★★★★☆ |
| Gorilla Technology Group | 32.75% | 122.61% | ★★★★★☆ |
Click here to see the full list of 67 stocks from our US High Growth Tech and AI Stocks screener.
Below we spotlight a couple of our favorites from our exclusive screener.
MiMedx Group (MDXG)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare, with a market capitalization of approximately $1.03 billion.
Operations: The company generates revenue primarily from its biotechnology segment, specifically targeting startups, with reported earnings of $363.77 million.
MiMedx Group, a player in the biotech sector focusing on advanced wound care, is navigating a challenging yet opportunistic landscape. Recently, the company raised its full-year revenue outlook to low double digits, reflecting optimism despite a dip in net income from $17.63 million to $9.62 million in Q2 2025 compared to the previous year. Their strategic alliance with Vaporox hints at aggressive moves into co-promotion and marketing of wound care products, potentially enhancing their market reach and product efficacy. This collaboration alongside an investment in Vaporox could bolster MiMedx's position by integrating innovative therapies like VHT into their offerings, which have shown promising results in clinical studies and real-world applications. Despite facing earnings volatility with a significant drop over the past year (-59.3%), forecasts suggest an earnings growth of 24.6% per annum over the next three years, outpacing both industry and market averages.
- Click to explore a detailed breakdown of our findings in MiMedx Group's health report.
- Learn about MiMedx Group's historical performance.
National CineMedia (NCMI)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: National CineMedia, Inc. operates a cinema advertising network in North America through its subsidiary, National CineMedia, LLC, with a market capitalization of $434.81 million.
Operations: The company generates revenue primarily from advertising, totaling $235.30 million.
Amid a challenging landscape, National CineMedia (NCMI) is navigating through significant financial turbulence, as evidenced by its Q2 2025 results with sales dropping from $54.7 million to $51.8 million year-over-year and a deepened net loss of $10.7 million compared to $8.7 million in the same period last year. Despite these setbacks, NCMI remains proactive, having repurchased shares worth $9.4 million in recent months and maintaining a consistent dividend payout ($0.03 per share). Looking ahead, the company projects an optimistic revenue increase for Q3 2025 to between $62 million and $67 million, signaling potential stabilization and growth amidst ongoing market challenges.
- Take a closer look at National CineMedia's potential here in our health report.
- Understand National CineMedia's track record by examining our Past report.
Simulations Plus (SLP)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Simulations Plus, Inc. specializes in creating software for drug discovery and development that leverages artificial intelligence and machine learning technologies, with a market cap of approximately $299.69 million.
Operations: SLP generates revenue primarily through its software and services segments, with software contributing $46.73 million and services adding $33.66 million. The company focuses on developing advanced modeling and simulation tools for drug discovery using AI and machine learning technologies.
Simulations Plus has demonstrated a robust commitment to innovation, particularly through its artificial intelligence-driven drug design (AIDD) initiatives, which recently yielded potent compounds for gene expression related to immune responses. Despite recent setbacks including being dropped from several S&P indices, the company's R&D focus remains strong with expenditures that align closely with its forward-looking revenue projections. With earnings expected to grow by an impressive 114.35% annually and a forecasted revenue increase of up to 14% in the coming fiscal year, Simulations Plus is strategically positioning itself in the high-stakes biotech sector, leveraging cutting-edge technology to potentially revolutionize therapeutic development.
- Dive into the specifics of Simulations Plus here with our thorough health report.
- Gain insights into Simulations Plus' historical performance by reviewing our past performance report.
Make It Happen
- Navigate through the entire inventory of 67 US High Growth Tech and AI Stocks here.
- Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
- Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.
Searching for a Fresh Perspective?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
